- Home
- COMP vs MRUS Comparison
COMP vs MRUS Comparison
Compare COMP & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COMP
- MRUS
- Stock Information
- Founded
- COMP 2012
- MRUS 2003
- Country
- COMP United States
- MRUS Netherlands
- Employees
- COMP N/A
- MRUS N/A
- Industry
- COMP EDP Services
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- COMP Technology
- MRUS Health Care
- Exchange
- COMP Nasdaq
- MRUS Nasdaq
- Market Cap
- COMP 3.9B
- MRUS 4.1B
- IPO Year
- COMP 2021
- MRUS 2016
- Fundamental
- Price
- COMP $6.36
- MRUS $52.85
- Analyst Decision
- COMP Buy
- MRUS Strong Buy
- Analyst Count
- COMP 6
- MRUS 12
- Target Price
- COMP $10.17
- MRUS $87.92
- AVG Volume (30 Days)
- COMP 7.3M
- MRUS 1.2M
- Earning Date
- COMP 07-30-2025
- MRUS 07-31-2025
- Dividend Yield
- COMP N/A
- MRUS N/A
- EPS Growth
- COMP N/A
- MRUS N/A
- EPS
- COMP N/A
- MRUS N/A
- Revenue
- COMP $5,931,200,000.00
- MRUS $54,732,000.00
- Revenue This Year
- COMP $25.51
- MRUS $75.57
- Revenue Next Year
- COMP $13.79
- MRUS $31.84
- P/E Ratio
- COMP N/A
- MRUS N/A
- Revenue Growth
- COMP 19.05
- MRUS 42.77
- 52 Week Low
- COMP $3.34
- MRUS $33.19
- 52 Week High
- COMP $10.25
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- COMP 47.42
- MRUS 51.76
- Support Level
- COMP $6.12
- MRUS $52.53
- Resistance Level
- COMP $6.58
- MRUS $54.00
- Average True Range (ATR)
- COMP 0.24
- MRUS 1.65
- MACD
- COMP 0.05
- MRUS -0.61
- Stochastic Oscillator
- COMP 51.41
- MRUS 19.77
About COMP Compass Inc.
Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.